Operating
D&A
Vertex Pharmaceuticals D&A increased by 3.1% to $55.70M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 19.8%, from $46.50M to $55.70M. Over 4 years (FY 2021 to FY 2025), D&A shows an upward trend with a 13.7% CAGR.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryEfficiency
SignalContext dependent
VolatilityStable
First reportedQ4 2013
Last reportedQ4 2025
How to read this metric
Higher levels typically reflect significant historical capital expenditures or acquisitions that are now being expensed over time.
Detailed definition
This metric represents the non-cash accounting charges used to allocate the cost of tangible assets and intangible asset...
Peer comparison
Capital-intensive hardware manufacturers generally show higher D&A relative to revenue than pure-play software companies.
Metric ID:
cf_depreciation_and_amortizationHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $31.24M | $31.70M | $33.83M | $35.90M | $37.30M | $36.70M | $38.40M | $38.80M | $41.40M | $42.10M | $59.00M | $53.50M | $54.00M | $53.20M | $46.50M | $48.40M | $51.70M | $54.00M | $55.70M |
| QoQ Change | — | +1.5% | +6.7% | +6.1% | +3.9% | -1.6% | +4.6% | +1.0% | +6.7% | +1.7% | +40.1% | -9.3% | +0.9% | -1.5% | -12.6% | +4.1% | +6.8% | +4.4% | +3.1% |
| YoY Change | — | — | — | — | +19.4% | +15.8% | +13.5% | +8.1% | +11.0% | +14.7% | +53.6% | +37.9% | +30.4% | +26.4% | -21.2% | -9.5% | -4.3% | +1.5% | +19.8% |
Range$31.24M – $59.00M
CAGR+13.7%
Avg YoY Growth+14.5%
Median YoY Growth+14.7%
Current Streak4 quarters growth
D&A at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's d&a?
- Vertex Pharmaceuticals (VRTX) reported d&a of $55.70M in Q4 2025.
- How has Vertex Pharmaceuticals's d&a changed year-over-year?
- Vertex Pharmaceuticals's d&a increased by 19.8% year-over-year, from $46.50M to $55.70M.
- What is the long-term trend for Vertex Pharmaceuticals's d&a?
- Over 4 years (2021 to 2025), Vertex Pharmaceuticals's d&a has grown at a 13.7% compound annual growth rate (CAGR), from $125.60M to $209.80M.
- What does d&a mean?
- The accounting process of spreading the cost of physical and intangible assets over time.